An FDA-approved growth hormone booster specifically studied for reducing deep belly fat (visceral fat). It's one of the most clinically validated peptides for improving body composition, with strong research behind it.
What to Expect
Week 1–2
Subtle changes in body composition beginning. Improved sleep quality. Mild injection site reactions common. GH/IGF-1 levels starting to rise.
Week 3–6
Measurable reduction in visceral adipose tissue. Improved lipid panel markers. Better body composition visible. Enhanced recovery from physical activity.
Week 8+
Significant visceral fat reduction (15%+ in clinical trials). Improved triglyceride and cholesterol levels. Sustained GH optimization without insulin resistance.
Common Side Effects
Scientific Overview
Tesamorelin is a synthetic 44-amino acid analog of human GHRH with a trans-3-hexenoic acid modification at the N-terminus for enhanced stability. FDA-approved for HIV-associated lipodystrophy, it selectively stimulates pituitary GH secretion and has demonstrated significant reduction in visceral adipose tissue (VAT) without affecting subcutaneous fat. Clinical trials showed 15% mean reduction in trunk fat with improved lipid profiles. Tesamorelin maintains physiological GH pulsatility and does not cause the insulin resistance associated with exogenous GH.
Dosing
2 mg subq daily, preferably before bed. Cycle for 12-26 weeks.
Practical Guide
Reconstitution
Mix 2mg vial with provided diluent (0.4mL sterile water). Swirl gently — do not shake.
Storage
Refrigerate vials. Use immediately after reconstitution (single-use vials). Do not freeze.
Injection Sites
Subcutaneous in abdomen only (as per FDA labeling). Do not inject into scar tissue, bruises, or navel area. Rotate sites.
Timing
Inject at the same time each day. Many physicians recommend evening or bedtime dosing.
Food
No specific food timing requirement per label.
Benefit Profile
Medical Considerations
Contraindications
- ✕Active cancer
- ✕Pregnancy/nursing (Category X)
- ✕Pituitary tumors or surgery
- ✕Hypersensitivity to tesamorelin or mannitol
Drug Interactions
Recommended Monitoring
- →IGF-1 levels every 3-6 months
- →Fasting glucose and HbA1c
- →CT or DEXA scan for visceral fat measurement
- →Monitor for fluid retention
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Published Research
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.
Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.
Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.
Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.